GB0034330679
© ACCESS Newswire
23.12.2025
AGL
LISTED
AIMX
Cellbxhealth PLC Announces Holding(s) in Company
News Preview
GUILDFORD, SURREY / ACCESS Newswire / December 23, 2025 / Cellbxhealth PLC: TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB0034330679Issuer NameCelLBxHealth plcUK or Non-UK IssuerUK2. Reason for NotificationAn acquisition or disposal of voting rights3. Details of person subject to the notification obligationNameConifer...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
05.11.2025
AGL
LISTED
AIMX
CelLBxHealth PLC Presents Proof-of-Concept Study
News Preview
CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conferenceParsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) GUILFORD, SURREY AND PLYMO...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
04.11.2025
AGL
LISTED
AIMX
Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding
News Preview
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of CTC testing into routine clinical practice within 5 yearsCTCs provide distinct and impactful information that is not captured by circulating tumour DNA (ctDNA)40% of the exp...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
16.10.2025
AGL
LISTED
AIMX
ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor
News Preview
GUILFORD, SURREY, AL / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with tests for use in research, drug development and clinical oncology, announces that it has strengthened its management team through two senior hires.Pete...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
08.10.2025
AGL
LISTED
AIMX
Angle PLC Announces Strategy Update
News Preview
Appointment of Executive Chairman, proposed change of name and strategy updateCompany to pursue revised strategy and name change to CelLBxHealth plcDr. Jan Groen, the current Non-Executive Chairman and recognised oncology diagnostic industry veteran, to lead company as Executive ChairmanRevised strategy to sharpen focus on the provision of industry...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.09.2025
AGL
LISTED
AIMX
Angle PLC Announces Presentation of Data on Glioblastoma
News Preview
CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma PatientsGBM CTC isolation only possible with Parsortix label-free methodologyData presented at the 7th ACTC meeting GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) so...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.09.2025
AGL
LISTED
AIMX
Angle PLC Announces Board Changes
News Preview
GUILDFORD, SURREY / ACCESS Newswire / September 12, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, following feedback and discussions with a significant shareholder, Andrew Newland, Chi...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.09.2025
AGL
LISTED
AIMX
Angle PLC Announces Interim Results
News Preview
ANGLE plc("ANGLE" or "the Company")Interim Results for the six months ended 30 June 2025COMMERCIALISATION PROGRESSED ACROSS MULTIPLE FRONTS DESPITE REVENUE PRESSURE FROM ADVERSE MARKET CONDITIONSLarge pharma contracts completed successfullyDNA Dual Analysis Illumina NGS assay for CTC-DNA and ctDNA developed GUILDFORD, SURREY / A...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.09.2025
AGL
LISTED
AIMX
Angle PLC Announces Change of Adviser
News Preview
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.06.2025
AGL
LISTED
AIMX
Angle PLC - EACR 2025: Data Demonstrating DNA Dual Analysis
News Preview
ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILINGPoster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour heterogeneity in lung cancer patients GUILDFORD, SURREY / ACCESS Newswire / June 17, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy compa...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.05.2025
AGL
LISTED
AIMX
Angle PLC Announces Notice of Results
News Preview
Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its preliminary results for the year...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
21.03.2025
AGL
LISTED
AIMX
Angle PLC Announces Results of Eisai Phase 2 pilot study
News Preview
UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZenecaResults of Eisai Phase 2 pilot study supports the capability of the Parsortix system for real-time assessment of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
21.03.2025
AGL
LISTED
AIMX
Angle PLC Announces Issue of LTIP Options and Share Options
News Preview
GUILDFORD, SURREY / ACCESS Newswire / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 11 July 2024 ("the Remuneration Policy"), the Remuneration Committee has approved the grant under the Lo...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2025
AGL
LISTED
AIMX
Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay
News Preview
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platformFindings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sampleANGLE invited to present data at EACR-Illumina webinar on 6 February 2025 GUILDFORD, SURREY / ACCESS Newswire / January 29, 2025 / ANGLE pl...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.01.2025
AGL
LISTED
AIMX
Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich
News Preview
CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatmentParsortix system used to identify patients with highly metastatic CTC clusters for targeted treatmentNew treatment strategy provides 'uncharted opportunity' to target metastasis responsible for the vast majority of cancer deaths GUILDFORD,...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.12.2024
AGL
LISTED
AIMX
Angle PLC Announces HER2 Presentation at SABCS
News Preview
WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUMIndependent findings support ANGLE's HER2 assay development programmePotential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a w...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.11.2024
AGL
LISTED
AIMX
Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR
News Preview
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug d...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
15.11.2024
AGL
LISTED
AIMX
Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR
News Preview
RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancerGUILDFORD, SURREY / ACCESSWIRE / Novem...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.11.2024
AGL
LISTED
AIMX
ANGLE presents two posters at EACR
News Preview
PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.11.2024
AGL
LISTED
AIMX
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
News Preview
ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progressionCTC analysis identifies druggable targ...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.10.2024
AGL
LISTED
AIMX
Angle PLC Announces Publication Demonstrates CTC Profiling Potential
News Preview
PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCERParsortix enriched CTCs detected at high rates in localised diseaseMulti-marker profiling of CTCs could support development of targeted therapies and help stratify patients in clinical trials GUILDFORD, SURREY / ACCESSWIRE / October 17, 2024 / ANGLE plc (AIM:A...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
26.09.2024
AGL
LISTED
AIMX
Angle PLC Announces 100th Publication Supporting Parsortix System Use
News Preview
GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repairANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
26.09.2024
AGL
LISTED
AIMX
Angle PLC Announces Half-year Report
News Preview
Interim Results for the six months ended 30 June 2024LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLYThree Large Pharma contracts secured each with substantial revenue potentialStrategic decision post period end to focus resources on pharma services GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / ANGLE plc ("ANGLE" or "the Compan...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
23.09.2024
AGL
LISTED
AIMX
Angle PLC Announces Exclusive agreement for DNA NGS panel
News Preview
ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBEOption for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs with ctDNACombining the Parsortix system with comprehensive DNA molecular analysis opens up a broad range of pharma services opportunities GUILDFORD, SURREY / ACCESSWIRE / Sept...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.09.2024
AGL
LISTED
AIMX
Angle PLC Announces Agreement with Recursion Pharmaceuticals
News Preview
New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.09.2024
AGL
LISTED
AIMX
Angle PLC Announces Notice of Interim Results and Webcast
News Preview
Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / September 17, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 Jun...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
